Sanofi, Glaxo advance talks to supply up to 300 mln COVID-19 vaccine doses to Europe -companies

Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions with the European Commission to supply up to 300 million doses of the drugmakers's experimental COVID-19 vaccine.

The doses would be manufactured in European countries including France, Belgium, Germany and Italy. Sanofi is leading the clinical development of the vaccine and expects to launch a pivotal trial by the end of this year.